In particular, patients with SA who continue to present with persistent hypereosinophilia after receiving anti IL-5/5R-targeted biologic treatment or eosinophilia despite maintenance OCSs, should undergo a re-evaluation of the SA diagnosis before being requalified for further SA asthma treatment. The gene discussed is IL5; the disease is asthma.